FDA Inspection 1132014 — Amarin Pharma, Inc.

Amarin Pharma, Inc. — FEI 3015820997

The FDA completed an inspection of Amarin Pharma, Inc. on Oct 6, 2020 in Bridgewater, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Oct 6, 2020
Fiscal Year
2021
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Bridgewater, NJ (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.